安非他酮
安慰剂
汉密尔顿抑郁量表
人口
不利影响
评定量表
医学
萧条(经济学)
临床试验
内科学
精神科
心理学
麻醉
重性抑郁障碍
戒烟
心情
替代医学
经济
病理
宏观经济学
发展心理学
环境卫生
作者
Lineberry Cg,Johnson Ja,Raymond Rn,Basil Samara,Feighner Jp,Harto Ne,Granacher Rp,Weisler Rh,Carman Js,Boyer Wf
出处
期刊:PubMed
日期:1990-05-01
卷期号:51 (5): 194-9
被引量:28
摘要
Two hundred twenty-four outpatients with major depression entered a 6-week, five-center, double-blind trial of bupropion 300 mg/day and placebo. A total of 216 patients were included in the efficacy analysis. In the combined center analysis, greater efficacy for bupropion was found on one or more measures (Hamilton Rating Scale for Depression, Montgomery-Asberg Depression Rating Scale, and Clinical Global Impressions) at treatment Days 21, 28, 35, and 42. Bupropion was well tolerated; only four adverse events were reported at least 5% more often in the bupropion group than in the placebo group. Six bupropion patients versus 5 placebo patients discontinued treatment because of adverse events. This study extends earlier findings of efficacy for higher-dose treatment in an inpatient population to lower-dose treatment in an outpatient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI